Fuzuloparib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase I drugs for Adenocarcinoma Of The Gastroesophageal Junction have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Fuzuloparib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Fuzuloparib overview
Fuzuloparib (IRuiyi) is a potent anti-neoplastic agent. It is formulated as capsules for oral route of administration. IRuiyi is indicated for the platinum-sensitive recurrent ovarian cancer, fallopian tube cancer and primary patients with germline BRCA mutation who have undergone second-line and above chemotherapy treatments.
Fuzuloparib (SHR-3162) is under development for the treatment of advanced esophageal squamous cell carcinoma , advanced solid malignancies including advanced pancreatic adenocarcinoma, HER2-negative metastatic breast cancer, recurrent or metastatic gastric cancer, prostate cancer, metastatic castration-resistant prostate cancer, recurrent ovarian cancer, peritoneal cancer, small cell lung cancer, fallopian tube cancer, glioblastoma multiforme (GBM) and refractory metastatic triple negative breast cancer. The therapeutic candidate is administered orally. The drug candidate is a small molecule which acts by targeting PARP-1 and PARP-2.
It was under development for the treatment of metastatic pancreatic cancer, squamous non-small cell lung cancer.
Jiangsu Hengrui Medicine overview
Jiangsu Hengrui Medicine (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US, and Japan. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland and Australia. Jiangsu Hengrui is headquartered in Lianyungang, Jiangsu Province, China.
For a complete picture of Fuzuloparib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
